ONCOTEX INC
At OncoTEX Inc., we’re on a mission to treat cancer effectively, without the prohibitive side effects we know today. We are addressing an urgent major unmet clinical need by transforming cancer therapy with TEX Core, an oncology drug platform that can create a new suite of life-changing cancer therapeutics.
ONCOTEX INC
Social Links:
Industry:
Biotechnology
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.oncotexinc.com
Total Employee:
251+
Status:
Active
Technology used in webpage:
Domain Not Resolving Person Schema
Official Site Inspections
http://www.oncotexinc.com Semrush global rank: 5.73 M Semrush visits lastest month: 1.46 K
- Host name: 172.65.190.172
- IP address: 172.65.190.172
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "OncoTEX Inc"
OncoTEX Inc - Crunchbase Company Profile & Funding
At OncoTEX Inc., we’re on a mission to treat cancer effectively, without the prohibitive side effects we know today. We are addressing an urgent major unmet clinical need by transforming …See details»
Oncotex Company Profile | Management and Employees List
Oncotex Profile and History. OncoTEX Inc. is an oncology company developing the next class of cancer therapeutics. OncoTEX owns TEX Core, a novel oncology drug platform that enables …See details»
Gold Technology for Immune Response Cancer Therapy Licensed …
Nov 3, 2021 About OncoTEX Inc. OncoTEX Inc is an oncology company and a member of the bioscience investment enterprise The iQ Group Global. OncoTEX Inc owns TEX Core, a novel …See details»
Chemical Society Reviews Journal Explores How OncoTEX’s Gold …
AUSTIN, Texas, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first in class cancer therapeutics that are well-tolerated, MRI-detectable, and target …See details»
OncoTEX Issued New U.S. Patent for Ovarian Cancer-Fighting
Mar 14, 2022 OncoTEX Inc. is an oncology company developing the next class of cancer therapeutics. OncoTEX owns TEX Core, a novel oncology drug platform that enables the …See details»
OncoTEX Issued New U.S. Patent for Ovarian Cancer …
Mar 14, 2022 New patent will broaden OxaliTEX’s U.S. claims and strengthen its IP portfolio.AUSTIN, Texas, March 14, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first-in-class ...See details»
OncoTEX & Sterling Pharma Solutions Sign Clinical Manufacturing …
OncoTEX Inc and Sterling Pharma Solutions recently announced that they had signed a clinical development agreement for the manufacture of OncoTex’s novel platinum-resistant oncology …See details»
Market announcement – IQX acquires interest in a new anticancer …
IQX Ltd (NSX: IQX) is pleased to announce that its Oncology franchise – OncoTEX Inc. – has acquired a novel anticancer drug platform. TEX Core is an anticancer drug platform that has …See details»
Press Release Distribution and Management - GlobeNewswire
AUSTIN, Texas, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first in class cancer therapeutics that are well-tolerated, MRI-detectable, and target …See details»
OncoTEX and Sterling sign clinical manufacturing …
May 13, 2021 OncoTEX Inc, an oncology company, and member of the iQ Group Global bioscience investment enterprise The iQ Group Global and Sterling Pharma Solutions, a global contract development and manufacturing …See details»
Promising Drug Candidate Licensed to Cancer Therapeutics …
Feb 7, 2022 AuraTEX, a gold-based cancer drug developed by University of Texas at Austin researchers, has been licensed exclusively to OncoTex Inc., a cancer therapeutics company.. …See details»
IQX Limited (NSX:IQX) Progress of Clinical Programs - ABN Newswire
The iQ Group Global Ltd is also pleased to announce that OncoTEX Inc, a US oncology therapeutic company, in which iQX Ltd holds 19% equity position, has signed a manufacturing …See details»
Gold Technology for Immune Response Cancer Therapy Licensed …
AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ -- OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased ...See details»
OncoTEX Receives Notice of Allowance for Patent in Korea
Mar 30, 2022 OncoTEX Inc. is an oncology company developing the next class of cancer therapeutics. OncoTEX owns TEX Core, a novel oncology drug platform that enables the …See details»
OncoTEX Issued New U.S. Patent for Ovarian Cancer-Fighting
AUSTIN, Texas, March 14, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first-in-class cancer pharmaceuticals that are tumor localizing, exhibit low side …See details»
OncoTEX Receives Notice of Allowance for Patent in Korea …
Mar 30, 2022 OncoTEX Inc. is an oncology company developing the next class of cancer therapeutics. OncoTEX owns TEX Core, a novel oncology drug platform that enables the …See details»
Gold Technology for Immune Response Cancer Therapy Licensed …
Nov 4, 2021 About OncoTEX Inc. OncoTEX Inc is an oncology company and member of the iQ Group Global bioscience investment enterprise The iQ Group Global. OncoTEX Inc owns TEX …See details»
OncoTEX Receives Notice of Allowance for Patent in Korea
AUSTIN, Texas, March 30, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing cancer pharmaceuticals that are tumor localizing, exhibit low side effects, target …See details»
Chemical Society Reviews Journal Explores How OncoTEX’s
AUSTIN, Texas, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first in class cancer therapeutics that are well-tolerated,...See details»
Gold Technology for Immune Response Cancer Therapy Licensed …
AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ -- Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEXSee details»